Search Results
PARTNER 3 What you should know about low risk TAVR
Overview of PARTNER 3 & Evolut Low Risk TAVR Trials
PARTNER 2A and SAPIEN 3 Results: Future of TAVR
TCT 2021: PARTNER 3: TAVR is Cost Effective Compared with SAVR for Low-Risk Patients
Low Risk TAVR: What the Data Tells Us (Michael J. Reardon, MD) March 26, 2020
Which Low-Risk Patients Should Receive TAVR?
TCT 23: 5Y Outcomes From the PARTNER 3 Low-Risk Trial
PARTNER 3 | TCT 2019
ACC 2020: Updates from the PARTNER 3 Trial — Dr Michael J Mack
Low-Risk TAVR at Least as Good as Surgery in Pivotal Trials - Medpage Today
Dr. Michael Mack on Partner 3 Outcomes
ACC 23: TAVR in Low-Risk Aortic Stenosis Patients: 3-Year Results From the Evolut Low Risk Trial
